Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers
Y A De Reus, P Hagedoorn, M G G Sturkenboom, F Grasmeijer, M S Bolhuis, I Sibum, H A M Kerstjens, H W Frijlink, O W Akkerman
PLOS ONE, doi:10.1371/journal.pone.0272034
Rationale Inhaled antimicrobials enable high local concentrations where needed and, compared to orally administration, greatly reduce the potential for systemic side effects. In SARS-CoV-2 infections, hydroxychloroquine sulphate (HCQ) administered as dry powder via inhalation could be safer than oral HCQ allowing higher and therefore more effective pulmonary concentrations without dose limiting toxic effects.
Objectives To assess the local tolerability, safety and pharmacokinetic parameters of HCQ inhalations in single ascending doses of 5, 10 and 20 mg using the Cyclops dry powder inhaler.
Methods Twelve healthy volunteers were included in the study. Local tolerability and safety were assessed by pulmonary function tests, electrocardiogram and recording adverse events. To estimate systemic exposure, serum samples were collected before and 0.5, 2 and 3.5 h after inhalation.
Results and discussion Dry powder HCQ inhalations were well tolerated by the participants, except for transient bitter taste in all participants and minor coughing irritation. There was no significant change in QTc-interval or drop in FEV 1 post inhalation. The serum HCQ concentration remained below 10 μg/L in all samples.
Supporting information
S1 Checklist. CONSORT checklist. (DOC)
Author Contributions
References
Armstrong, Gluck, Crapo, Jones, Hughes, Lung tissue volume estimated by simultaneous radiographic and helium dilution methods, Thorax,
doi:10.1136/thx.37.9.676Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis,
doi:10.1016/j.ijid.2020.06.099Brun, De Boer, Mannes, De Fraiture, Brimicombe et al., Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients, Eur J Pharm Biopharm,
doi:10.1016/s0939-6411%2802%2900044-9Chen, Efficacy of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of a randomized clinical trial
Cortegiani, Ingoglia, Ippolito, Giarratano, Einav, A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19, J Crit Care,
doi:10.1016/j.jcrc.2020.03.005Costedoat-Chalumeau, Dunogue, Morel, Guern, Guettrot-Imbert, Hydroxychloroquine: a multifaceted treatment in lupus, Presse Med,
doi:10.1016/j.lpm.2014.03.007Devaux, Rolain, Colson, Raoult, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105938Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends,
doi:10.5582/bst.2020.01047Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105949Geleris, Sun, Platt, Zucker, Baldwin et al., Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2012410Geller, Konstan, Smith, Noonberg, Conrad, Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety, Pediatr Pulmonol,
doi:10.1002/ppul.20594Gies, Bekaddour, Dieudonne, Guffroy, Frenger et al., Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine, Front Immunol,
doi:10.3389/fimmu.2020.01409Graham, Steenbruggen, Miller, Barjaktarevic, Cooper et al., Standardization of Spirometry 2019 Update, An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med,
doi:10.1164/rccm.201908-1590STGrasmeijer, Kerstjens, Frijlink, Van Der Vaart, Vonk, Colistin dry powder inhalation with the Twincer: An effective and more patient friendly alternative to nebulization, PLoS One,
doi:10.1371/journal.pone.0239658Hammond, Leister-Tebbe, Gardner, Abreu, Wisemandle, Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2118542Harris, Taylor, Minor, Elliott, Fernandez et al., The REDCap consortium: Building an international community of software platform partners, J Biomed Inform,
doi:10.1016/j.jbi.2019.103208Harris, Taylor, Thielke, Payne, Gonzalez et al., Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform,
doi:10.1016/j.jbi.2008.08.010Harrison, Mccarthy, Fleming, Hickey, Shortt et al., Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF), J Cyst Fibros,
doi:10.1016/j.jcf.2014.04.004Hoppentocht, Akkerman, Hagedoorn, Alffenaar, Van Der Werf et al., Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients, PLoS One,
doi:10.1371/journal.pone.0149768Hoppentocht, Akkerman, Hagedoorn, Frijlink, De Boer, The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer family, Eur J Pharm Biopharm,
doi:10.1016/j.ejpb.2015.01.012Horby, Mafham, Linsell, Bell, Staplin et al., Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2022926Kavanagh, Healy, Dayton, Robinson, Reilly et al., Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19, Med Hypotheses,
doi:10.1016/j.mehy.2020.110110Klimke, Hefner, Will, Voss, Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection, Med Hypotheses,
doi:10.1016/j.mehy.2020.109783Kuba, Imai, Rao, Gao, Guo et al., A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury, Nat Med,
doi:10.1038/nm1267Kuznik, Bencina, Svajger, Jeras, Rozman et al., Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines, J Immunol,
doi:10.4049/jimmunol.1000702Lammers, Brohet, Theunissen, Koster, Rood et al., Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients, Int J Infect Dis
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov,
doi:10.1038/s41421-020-0156-0Mahe ´vas, No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: Results of a study using routinely collected data to emulate a target trial, MedRxiv
Mdel, Aguilar-Fernandez, Cabrera-Roca, Idiopathic pulmonary haemosiderosis in childhood: a good response to systemic steroids
Mingo, Simmons, Shoemaker, Nelson, Schornberg et al., Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step, J Virol,
doi:10.1128/JVI.03398-14Mulay, Konda, Garcia, Yao, Beil et al., SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery, bioRxiv,
doi:10.1101/2020.06.29.174623Nicol, Joshi, Rizk, Sabato, Savic et al., Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection, Clin Pharmacol Ther,
doi:10.1002/cpt.1993Pauli, Joshi, Vasavada, Brackett, Towa, Evaluation of an Immediate-Release Formulation of Hydroxychloroquine Sulfate With an Interwoven Pediatric Taste-Masking System, J Pharm Sci,
doi:10.1016/j.xphs.2019.12.014Schrezenmeier, Dorner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat Rev Rheumatol,
doi:10.1038/s41584-020-0372-xSubbarao, Mcauliffe, Vogel, Fahle, Fischer et al., Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice, J Virol,
doi:10.1128/jvi.78.7.3572-3577.2004Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ,
doi:10.1136/bmj.m1849Uttley, Harnan, Cantrell, Taylor, Walshaw et al., Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis, Eur Respir Rev,
doi:10.1183/09059180.00001513Westerman, Boer, Brun, Touw, Roldaan et al., Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study, J Cyst Fibros,
doi:10.1016/j.jcf.2006.10.010White, Watson, Hoglund, Chan, Cheah et al., COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology, PLoS Med,
doi:10.1371/journal.pmed.1003252Who, None
Yao, Ye, Zhang, Cui, Huang et al., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Zhou, Dai, Tong, COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J Antimicrob Chemother,
doi:10.1093/jac/dkaa114Zhou, Dcosta, Landau, Tada, Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies, Viruses,
doi:10.3390/v14061334Zhu, Zhang, Li, Yang, Song, A Novel Coronavirus from Patients with Pneumonia in China, N Engl J Med,
doi:10.1056/NEJMoa2001017
